CAM ProgramFourth generation CAM program
Fourth generation CAMs are being developed for the treatment of HBV
Derived from a novel chemical scaffold, capsid assembly modulators (CAMs) have shown strong in vitro and in vivo activity in a transgenic mouse model of hepatitis B virus (HBV) infection.1
Early in vivo data point to a differentiated mechanism of action (MOA) which prevents accumulation of empty capsids, unlike most CAMs, and potentially provides for a more targeted, productive clearance by the immune system.1
Why fourth generation CAMs?
Fourth generation CAMs result in more potent viral suppression than earlier generations, as measured by 2 key markers of HBV replication1
ATI-1428 and ATI-1645 deeply inhibit HBV replication and prevent cccDNA establishment without causing liver damage.1
Our CAMs have the potential to synergize with our ASPIN, ATI-2173, and target different stages of the HBV life cycle.1
CAM program selected for unique mechanism of action1
- Traditional CAMs being developed by others induce retention of hepatitis B core antigen (HBcAg), while Antios’ proprietary novel CAMs (ATI-1428 and ATI-1645) do not1
- The retention of HBcAg empty capsid could be a clinical safety liability and a decoy for functional immune-based clearance1
- Competitor CAMs have on- and off-treatment ALT flares in their clinical programs1
Reference: 1. Data on file. Antios Therapeutics, Doylestown, PA.